Windward Bio

Privately held: no public share price · Switzerland / United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
TSLPMonoclonal antibody
Chronic Obstructive Pulmonary DiseaseAsthma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
WIN378Phase 2COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-12-17 · NCT07646587 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
WIN378Phase 2Asthma
Est. primary completion 2028-10-01 · NCT07120503 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultWIN378 (HBM9378)Positive interim results from the Phase 2 portion of POLARIS-1 (WIN378/HBM9378, asthma); Phase 3 portion started
Windward Bio · Source ↗

Financial reports

No financial reports recorded.